Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5
A compound useful as a Sirt2 or Sirt5 inhibitor having the formula (1) wherein: R 1 is a hydrocarbon group having at least two carbon atoms connected by carbon-carbon bonds, wherein said hydrocarbon group is optionally endcapped by a neutral or anionic oxygen-containing group; R 2a , R 2b , and R 2c are independently selected from hydrogen atom and hydrocarbon groups; X 0 , X 1 , X 2 , and X 3 are independently selected from —(CH 2 ) n —, —NR 5 —, —O—, —S—, and a bond, wherein n represents 1, 2, or 3, provided that at least one of X 0 -X 3 is —(CH 2 ) n —; and R 3 and R 4 are independently selected from the group consisting of hydrogen atom, hydrocarbon groups, biological groups, and protecting groups. Also described are pharmaceutical compositions of the inhibiting compounds, and methods of treatment by administration of the inhibiting compounds.
1. A compound useful as a Sirt2 or Sirt5 inhibitor having the formula:
wherein:
R 1 is a carboxylate salt, carboxylic acid, carboxylic acid ester, or thiocarboxylate group;
R 2a , R 2b , and R 2c are independently selected from hydrogen atom and methyl groups;
X 0 , X 1 , X 2 , and X 3 are independently selected from —(CH 2 ) n — and a bond, wherein n represents 1, 2, or 3, provided that at least one of X 0 -X 3 is —(CH 2 ) n —; and
R 3 is selected from hydrocarbon groups containing 1-20 carbon atoms and optionally containing one or more heteroatoms selected from oxygen, nitrogen, sulfur, and halogen atoms; and R 4 comprises a cyclic hydrocarbon group optionally containing one or more heteroatoms selected from oxygen, nitrogen, sulfur, and halogen atoms.
2. The compound of claim 1 , wherein R 1 is a carboxylate salt, carboxylic acid, or carboxylic acid ester group, wherein the ester group on said carboxylic acid ester is optionally a protecting group.
3. The compound of claim 1 , wherein said compound has the following formula:
wherein:
R 1 is a carboxylate salt, carboxylic acid, carboxylic acid ester, or thiocarboxylate group;
R 2a , R 2b , and R 2 c are independently selected from hydrogen atom and methyl groups; X 0 , X 1 , X 2 , and X 3 are independently selected from —(CH 2 )— and a bond, wherein n represents 1, 2, or 3, provided that at least one of X 0 -X 3 is —(CH 2 );
R 6 and R 7 are independently selected from hydrogen atom, unsubstituted hydrocarbon groups having up to six carbon atoms, and heteroatom-containing groups;
Y 1 and Y 2 are independently selected from —O—, —NR 5 —, —S—, —CH 2 —, —CH 2 O—, —CH 2 NR 5 —, and —CH 2 S— groups; and
R 5 is independently selected from hydrogen atom and methyl groups.
4. A pharmaceutical composition comprising a compound according to Formula (1) in claim 1 dispersed in a pharmaceutically acceptable carrier.
5. The compound of claim 1 , wherein X 0 , X 1 , X 2 , and X 3 are each —CH 2 —.
6. The compound of claim 1 , wherein R 3 comprises a protecting group.
7. The compound of claim 6 , wherein the protecting group is selected from the group consisting of benzyloxycarbonyl (Cbz), p-methoxybenzylcarbonyl, t-butyloxycarbonyl (BOC), acetyl (Ac), benzoyl, and tosyl groups.
8. The compound of claim 1 , wherein R 4 comprises a cyclic hydrocarbon.
9. The compound of claim 8 , wherein said cyclic hydrocarbon is unsaturated.
10. The compound of claim 1 , wherein R 2a , R 2b , and R 2c are hydrogen atoms.